Management of infection prophylaxis in Dutch patients with myelodysplastic syndromes, a web-based case vignette questionnaire: The MINDSET study.
anti-infective agent
infections
myelodysplastic syndromes
prophylaxis
survey
Journal
European journal of haematology
ISSN: 1600-0609
Titre abrégé: Eur J Haematol
Pays: England
ID NLM: 8703985
Informations de publication
Date de publication:
Oct 2022
Oct 2022
Historique:
revised:
21
06
2022
received:
25
04
2022
accepted:
22
06
2022
pubmed:
27
6
2022
medline:
14
9
2022
entrez:
26
6
2022
Statut:
ppublish
Résumé
Infections are a major cause of morbidity and mortality in patients with myelodysplastic syndromes (MDS). The objective of the MINDSET study was to evaluate haematologists' management of infection prevention in MDS patients using a case vignette study and to assess the availability of guidelines. We conducted a web-based, nationwide survey amongst haematologists in the Netherlands between September and December 2021. The survey included a set of case vignettes. In addition, the availability of protocols was evaluated. Sixty responses were obtained (23.6%). These responses were well distributed across hospital types as well as level of experience. No protocols regarding infection prophylaxis specifically for MDS patients were received. In the case vignette of a 75-year-old MDS patient, respondents would primarily prescribe infection prophylaxis in case of recurrent infections (96.7%) and neutropenia (75.0% for absolute neutrophil count [ANC] < 0.2 × 10 This study showed diverse reasons and considerations of haematologists regarding whether to prescribe infection prophylaxis in MDS patients. Given the seriousness of infections in MDS patients, patient-tailored recommendations might be valuable in clinical decision-making.
Identifiants
pubmed: 35753043
doi: 10.1111/ejh.13820
pmc: PMC9544536
doi:
Substances chimiques
Antifungal Agents
0
Lenalidomide
F0P408N6V4
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
381-387Informations de copyright
© 2022 The Authors. European Journal of Haematology published by John Wiley & Sons Ltd.
Références
Ann Hematol. 2016 May;95(6):937-44
pubmed: 27025507
Blood. 2010 Jan 21;115(3):453-74
pubmed: 19880497
Ann Hematol. 2015 Aug;94(8):1373-9
pubmed: 25869027
N Engl J Med. 2009 Nov 5;361(19):1872-85
pubmed: 19890130
J Natl Compr Canc Netw. 2022 Feb;20(2):106-117
pubmed: 35130502
Cancer. 2010 May 1;116(9):2174-9
pubmed: 20162709
EJHaem. 2022 Mar 25;3(3):775-784
pubmed: 36051088
Leuk Res. 2020 Sep;96:106419
pubmed: 32683127
Blood. 2008 Jul 1;112(1):45-52
pubmed: 18443215
Blood Adv. 2020 Aug 25;4(16):4029-4044
pubmed: 32841339
Blood Rev. 2019 Mar;34:16-25
pubmed: 30448050
Int J Environ Res Public Health. 2020 Dec 21;17(24):
pubmed: 33371225
Am J Hematol. 2013 Feb;88(2):130-4
pubmed: 23345248
BMJ. 1996 Jan 13;312(7023):71-2
pubmed: 8555924
J Antimicrob Chemother. 2018 Dec 1;73(12):3221-3230
pubmed: 30085172
Expert Rev Hematol. 2016 Jun;9(6):607-14
pubmed: 27100058
J Clin Oncol. 2018 Oct 20;36(30):3043-3054
pubmed: 30179565
Br J Haematol. 2018 Jun;181(5):614-627
pubmed: 29707769
Haematologica. 2012 Oct;97(10):1459-70
pubmed: 22733024
J Natl Compr Canc Netw. 2016 Jul;14(7):882-913
pubmed: 27407129
Ann Oncol. 2021 Feb;32(2):142-156
pubmed: 33221366
Int J Public Health. 2018 Jul;63(6):765-773
pubmed: 29691594
Ann Hematol. 2017 Nov;96(11):1833-1840
pubmed: 28803258
Int J Environ Res Public Health. 2021 Jul 18;18(14):
pubmed: 34300079
Blood. 2016 May 19;127(20):2391-405
pubmed: 27069254
Mediterr J Hematol Infect Dis. 2018 Jul 01;10(1):e2018039
pubmed: 30002795
Br J Haematol. 2021 Jul;194(2):267-281
pubmed: 34180045
Eur J Haematol. 2022 Oct;109(4):381-387
pubmed: 35753043
Blood Adv. 2021 Mar 9;5(5):1344-1351
pubmed: 33656535
Transpl Infect Dis. 2013 Dec;15(6):652-7
pubmed: 24010918
Eur J Cancer. 2014 Mar;50(5):1004-12
pubmed: 24388662